Prehľad v Nature Medicine pojednáva o rozšírení liekov na báze glukagónu podobného peptidu-1 (GLP-1) za hranice cukrovky 2. typu a obezity. It outlines opportunities for new indications for these drugs. It covers key questions about their benefits. He is interested in long-term security. It identifies areas of uncertainty that require further research. The article was published online on 2 January 2026 with doi:10.1038/s41591-025-04124-5.